The TGF-β superfamily cytokine Activin-A is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation.


Journal

Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918

Informations de publication

Date de publication:
09 02 2021
Historique:
received: 13 07 2020
revised: 12 10 2020
accepted: 16 12 2020
pubmed: 10 1 2021
medline: 8 9 2021
entrez: 9 1 2021
Statut: ppublish

Résumé

Th17 cells are known to exert pathogenic and non-pathogenic functions. Although the cytokine transforming growth factor β1 (TGF-β1) is instrumental for Th17 cell differentiation, it is dispensable for generation of pathogenic Th17 cells. Here, we examined the T cell-intrinsic role of Activin-A, a TGF-β superfamily member closely related to TGF-β1, in pathogenic Th17 cell differentiation. Activin-A expression was increased in individuals with relapsing-remitting multiple sclerosis and in mice with experimental autoimmune encephalomyelitis. Stimulation with interleukin-6 and Activin-A induced a molecular program that mirrored that of pathogenic Th17 cells and was inhibited by blocking Activin-A signaling. Genetic disruption of Activin-A and its receptor ALK4 in T cells impaired pathogenic Th17 cell differentiation in vitro and in vivo. Mechanistically, extracellular-signal-regulated kinase (ERK) phosphorylation, which was essential for pathogenic Th17 cell differentiation, was suppressed by TGF-β1-ALK5 but not Activin-A-ALK4 signaling. Thus, Activin-A drives pathogenic Th17 cell differentiation, implicating the Activin-A-ALK4-ERK axis as a therapeutic target for Th17 cell-related diseases.

Identifiants

pubmed: 33421362
pii: S1074-7613(20)30538-0
doi: 10.1016/j.immuni.2020.12.010
pmc: PMC7878438
mid: NIHMS1659077
pii:
doi:

Substances chimiques

Transforming Growth Factor beta 0
activin A 0
Activins 104625-48-1
Activin Receptors, Type I EC 2.7.11.30
Acvr1b protein, mouse EC 2.7.11.30

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

308-323.e6

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI123193
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI131238
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI160774
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

J Immunol. 2009 Aug 1;183(3):1715-23
pubmed: 19570828
Nat Rev Immunol. 2017 Sep;17(9):535-544
pubmed: 28555673
Cytokine Growth Factor Rev. 2013 Jun;24(3):285-95
pubmed: 23541927
Nat Immunol. 2007 Dec;8(12):1390-7
pubmed: 17994024
Science. 1994 Apr 1;264(5155):101-4
pubmed: 8140412
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
Annu Rev Immunol. 2009;27:485-517
pubmed: 19132915
Nature. 2017 Nov 2;551(7678):105-109
pubmed: 29072299
Cell. 2014 Oct 9;159(2):440-55
pubmed: 25263330
Trends Endocrinol Metab. 2005 Mar;16(2):73-8
pubmed: 15734148
Cell. 2020 Jan 9;180(1):79-91.e16
pubmed: 31866067
Mol Cell Endocrinol. 2012 Aug 15;359(1-2):101-6
pubmed: 22037168
Nature. 2011 Jul 17;475(7357):514-8
pubmed: 21765430
Nat Rev Mol Cell Biol. 2018 Jul;19(7):419-435
pubmed: 29643418
Cell. 2006 Jul 28;126(2):375-87
pubmed: 16873067
Nat Immunol. 2012 Oct;13(10):991-9
pubmed: 22961052
Nature. 2006 May 11;441(7090):235-8
pubmed: 16648838
Cell Commun Signal. 2009 Jun 18;7:15
pubmed: 19538713
Immunity. 2006 Feb;24(2):179-89
pubmed: 16473830
Nat Rev Immunol. 2016 Nov 25;16(12):723-740
pubmed: 27885276
Mol Cancer. 2015 Oct 24;14:182
pubmed: 26497569
Cytokine Growth Factor Rev. 2009 Apr;20(2):153-64
pubmed: 19261538
Immunity. 2018 Apr 17;48(4):745-759.e6
pubmed: 29669252
Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12269-12280
pubmed: 32409602
Immunity. 2020 Feb 18;52(2):328-341.e5
pubmed: 32049050
Semin Immunopathol. 2013 Jul;35(4):481-99
pubmed: 23385857
Immunity. 2007 May;26(5):579-91
pubmed: 17481928
Eur J Endocrinol. 2001 Sep;145(3):225-36
pubmed: 11517001
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
J Virol. 1996 Aug;70(8):5701-5
pubmed: 8764092
Trends Immunol. 2011 Sep;32(9):395-401
pubmed: 21782512
Sci Signal. 2019 Feb 26;12(570):
pubmed: 30808818
Eur J Immunol. 2013 Jul;43(7):1716-26
pubmed: 23620016
Nat Rev Immunol. 2007 Jun;7(6):443-53
pubmed: 17525753
J Cell Sci. 2005 Aug 15;118(Pt 16):3573-84
pubmed: 16105881
J Allergy Clin Immunol. 2012 Apr;129(4):1000-10.e3
pubmed: 22277204
Wiley Interdiscip Rev Dev Biol. 2013 Jan-Feb;2(1):47-63
pubmed: 23799630
Cold Spring Harb Perspect Biol. 2016 Aug 01;8(8):
pubmed: 27481709
Cell. 2006 Mar 24;124(6):1283-98
pubmed: 16564017
Cell. 2015 Dec 3;163(6):1400-12
pubmed: 26607794
Nat Rev Immunol. 2006 Apr;6(4):329-33
pubmed: 16557264
Nature. 2006 May 11;441(7090):231-4
pubmed: 16648837
Nat Immunol. 2018 Oct;19(10):1126-1136
pubmed: 30201991
Cell. 2015 Dec 3;163(6):1413-27
pubmed: 26607793
Cell Rep. 2018 Mar 6;22(10):2642-2653
pubmed: 29514093
J Immunol. 2006 Nov 15;177(10):6787-94
pubmed: 17082592
Immunity. 2019 Jul 16;51(1):77-89.e6
pubmed: 31229354
J Biol Chem. 2010 Sep 17;285(38):29039-43
pubmed: 20667820
J Autoimmun. 2019 Nov;104:102314
pubmed: 31416681
Immunity. 2011 Mar 25;34(3):396-408
pubmed: 21435587
J Exp Med. 2001 Sep 3;194(5):629-44
pubmed: 11535631
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10878-83
pubmed: 12949259
J Immunol. 2009 Apr 15;182(8):4633-40
pubmed: 19342638
Nature. 2010 Oct 21;467(7318):967-71
pubmed: 20962846
J Biol Chem. 2005 Jun 10;280(23):22115-23
pubmed: 15817471
Immunity. 2006 Jun;24(6):677-88
pubmed: 16782025
Cytokine Growth Factor Rev. 2006 Jun;17(3):157-71
pubmed: 16481210
Nat Immunol. 2016 Aug;17(8):976-84
pubmed: 27376469

Auteurs

Bing Wu (B)

Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Song Zhang (S)

Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Zengli Guo (Z)

Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Yanmin Bi (Y)

Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Mingxia Zhou (M)

Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Ping Li (P)

Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Maryamsadat Seyedsadr (M)

Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Xiaojiang Xu (X)

Integrative Bioinformatics, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.

Jian-Liang Li (JL)

Integrative Bioinformatics, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.

Silva Markovic-Plese (S)

Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Yisong Y Wan (YY)

Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: wany@email.unc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH